Showing 2391-2400 of 5644 results for "".
- Oyster Point’s Tyrvaya Nasal Spray for Dry Eye Disease is Now Available at US Regional Wholesalershttps://modernod.com/news/oyster-points-tyrvaya-nasal-spray-for-dry-eye-disease-is-now-available-at-us-regional-wholesalers/2480399/Oyster Point Pharma announced that Tyrvaya (varenicline solution) Nasal Spray 0.03 mg is now available at US regional wholesalers for distribution to pharmacies. The FDA approved Tyrvaya Nasal Spray for the treatment of the signs and symptoms of dry eye disease on O
- Visus Therapeutics Appoints David Guyer, MD, as Chairman of the Board, and Names Ted Danse as Head of Business Developmenthttps://modernod.com/news/visus-therapeutics-appoints-david-guyer-md-as-chairman-of-the-board-and-names-ted-danse-as-head-of-business-development/2480395/Visus Therapeutics announced the appointment of ophthalmology and industry expert David Guyer, MD, as the chairman of the Board after serving as an advisor since the company’s inception, and life sciences veteran Ted Danse as the head of business development. “I&rs
- Tilak Healthcare Raises €7m to Deploy Its Remote Vision Monitoring Platformhttps://modernod.com/news/tilak-healthcare-raises-eur7m-to-deploy-its-remote-vision-monitoring-platform/2480381/Tilak Healthcare, a developer of mobile games with medical modules to monitor patients with chronic ophthalmological conditions, has announced a €7 million fundraising round managed by Elaia, with the participation of Swen Capital Partners, Matmut Innovation, and co-founder
- Collaboration Agreement Aims to Develop Orally Administered Treatment for Diabetic Macular Edema and Wet AMDhttps://modernod.com/news/collaboration-agreement-aims-to-develop-orally-administered-treatment-for-diabetic-macular-edema-and-wet-amd/2480380/Korea-based biopharmaceutical company Curacle announced that it has entered into an exclusive license and collaboration agreement with Théa Open Innovation (TOI) for the development and commercialization of Curacle's CU06-RE, which is being examined as an orall
- Eyenovia Announces Reclassification of MydCombi as Drug-Device Combination Product by FDAhttps://modernod.com/news/eyenovia-announces-reclassification-of-mydcombi-as-drug-device-combination-product-by-fda/2480375/In a Complete Response Letter (CRL) from the FDA, Eyenovia announced that MydCombi, the company’s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, has been reclassified as a drug-device com
- FDA Approves Genentech’s Port Delivery System, Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet AMDhttps://modernod.com/news/fda-approves-genentechs-port-delivery-system-susvimo-a-first-of-its-kind-therapeutic-approach-for-wet-amd/2480373/Genentech announced that the FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with wet age-related macular degeneration (AMD) who have previously responded to at least two anti-vascular endothelial growth fact
- Retrotope Reports Positive Results from Studies of RT011 in Animal Models of Retinal Degenerationhttps://modernod.com/news/retrotope-reports-positive-results-from-studies-of-rt011-in-animal-models-of-retinal-degeneration/2480361/Retrotope announced that positive results from preclinical studies of RT011, the second compound to emerge from the company’s novel technology platform, are being reported
- Registration Now Open for International Sports Vision Association 6th Annual Conferencehttps://modernod.com/news/registration-now-open-for-international-sports-vision-association-6th-annual-conference/2480360/Registration is now open for Elevating Athletic Performance<
- Quantel Medical Launches Website Dedicated to Laser Therapies for Retinal Disordershttps://modernod.com/news/quantel-medical-launches-website-dedicated-to-laser-therapies-for-retinal-disorders/2480357/Quantel Medical announced its new website, www.subliminal-laser-therapy.com, dedicated to laser therapies for retinal disorders. "Over the years, the development and introduction of new and innovative laser technologies has
- Amidst the COVID-19 Pandemic, Early Intervention Remains an Obstacle for Overall Eye Health Despite Fear of Blindnesshttps://modernod.com/news/amidst-the-covid-19-pandemic-early-intervention-remains-an-obstacle-for-overall-eye-health-despite-fear-of-blindness/2480352/Globally, most adults, 70 percent, don’t plan to get their eyes examined this year, despite acknowledging the critical importance of eye health. These new findings come from a comprehensive, large-scale Johnson & Johnson Vision Global Eye Health Survey announced in advance of World Sigh